Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19

Joydeb Majumder, Tamara Minko, Joydeb Majumder, Tamara Minko

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.

Keywords: ARDS; anti-SARS-CoV-2 antibody; antiviral drugs; antiviral vaccines; convalescent plasma therapy; immunotherapy; nanotherapeutics.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Human coronavirus. a Schematic structure of SARS-CoV-2 virus. b A transmission electron microscope image of SARS-CoV-2 spherical viral particles in cell. The virus is colorized in blue. Adapted from the US Centers for Disease Control. Reproduced with permission from (16)
Fig. 2
Fig. 2
Overview of the coronavirus replication cycle (simplified, not to scale). The figure depicts viral development from initial binding and release of viral genome to eventual exocytosis of the mature virion. ERGIC, endoplasmic reticulum-Golgi intermediate compartment (also referred to as vesicular-tubular cluster). Drawn using a template retrieved from (18)
Fig. 3
Fig. 3
Proposed therapeutic treatments for COVID-19. a, b Targeting viral entry mechanism. a Viral entry mechanism of SARS-CoV-2. b Possible approaches for blocking ACE2 receptors. c Antiviral drugs targeting the coronavirus replication cycle (simplified). Abbreviations: ACE2, angiotensin-converting enzyme 2; scFvs, recombinant human single-chain variable region fragments against the S1 domain of spike (S) protein of the SARS-CoV; ACE2-Fc, immunoglobulin fragment (Fc)-ACE2 fusion protein
Fig. 4
Fig. 4
Acute Immune responses to coronaviruses. Coronaviruses are RNA viruses, some of which can infect human lung epithelium via the receptor ACE2 (1). After endocytosis (2), viral RNA activates endosomal and cytoplasmic sensors, TLR3/7 and MAVS, respectively (3). These receptors activate interferon regulatory factors (IRFs) and NFkB (4) to induce inflammatory cytokines (5), including interferons (IFNs). Dendritic cells (DCs) sample antigen and migrate to lymphoid organs to prime adaptive immunity. CD8 T cells recognize of antigen on DCs or infected cells (6) and induce apoptosis in affected lung epithelial cells (7)
Fig. 5
Fig. 5
Common components of vaccines. Vaccines include various components such as active ingredients, adjuvants, antibiotics, stabilizers, preservatives, and traces of residual inactivating agents as schematically shown here
Fig. 6
Fig. 6
Clinical phase vaccine candidates for COVID-19 (as of April, 2020). Based on data from (36)
Fig. 7
Fig. 7
A typical procedure of COVID-19 diagnostics through RT-PCR. The RT-PCR method involves sample collection and extraction of viral RNA sample. The extracted RNA sample is converted to its complementary DNA (cDNA) by the reverse transcription. Finally, the amplification of this DNA sample is performed in qPCR, and the viral cDNA is detected by a fluorescent signal
Fig. 8
Fig. 8
Assay techniques and tests for COVID-19 diagnosis. a, b The enzyme-linked immunosorbent assays (ELISA) detecting COVID-19 antibodies (a) or antigens (b). Redrawn with permission from (155). c Serologic diagnostic tests for COVID-19 antibodies
Fig. 9
Fig. 9
Representative chest CT images. a Transverse chest CT images from a 40-year-old man showing bilateral multiple lobular and subsegmental areas of consolidation on day 15 after symptom onset. b Transverse chest CT images from a 53-year-old woman showing bilateral ground-glass opacity and subsegmental areas of consolidation on day 8 after symptom onset. c Transverse chest CT images showing bilateral ground-glass opacity on day 12 after symptom onset. Reproduced with permission from (183)

References

    1. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660–694. doi: 10.1128/CMR.00023-07.
    1. Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 a (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895–4902. doi: 10.1016/j.vaccine.2010.05.031.
    1. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995–1007. doi: 10.1016/s0140-6736(15)60454-8.
    1. Oleribe OO, Salako BL, Ka MM, Akpalu A, McConnochie M, Foster M, et al. Ebola virus disease epidemic in West Africa: lessons learned and issues arising from West African countries. Clin Med. 2015;15:54–57. doi: 10.7861/clinmedicine.15-1-54.
    1. Agumadu VC, Ramphul K. Zika virus: a review of literature. Cureus. 2018;10(7):e3025. doi: 10.7759/cureus.3025.
    1. World Health, Organization. Novel coronavirus (2019-nCoV): situation report, 1. Geneva: World Health Organization; 2020. . Accessed 2020-01-21.
    1. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544. doi: 10.1038/s41564-020-0695-z.
    1. Eurosurveillance Editorial Team Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveil. 2020;25(5):200131e. doi: 10.2807/1560-7917.ES.2020.25.5.200131e.
    1. WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health, Organization (WHO); 2020. .
    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91((1):157–160. doi: 10.23750/abm.v91i1.9397.
    1. Coronavirus disease (COVID-19) pandemic. World Health Organization; 2020 [cited 2020 10/31/2020]; Available from: .
    1. Li C, Ji F, Wang L, Wang L, Hao J, Dai M, Liu Y, Pan X, Fu J, Li L, Yang G, Yang J, Yan X, Gu B. Asymptomatic and human-to-human transmission of SARS-CoV-2 in a 2-family cluster, Xuzhou, China. Emerg Infect Dis. 2020;26(7):1626–1628. doi: 10.3201/eid2607.200718.
    1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi: 10.1056/NEJMoa2001017.
    1. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi: 10.1016/j.tim.2016.03.003.
    1. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729–734. doi: 10.1016/j.cmi.2020.03.026.
    1. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822–3835. doi: 10.1021/acsnano.0c02624.
    1. Khan I, Ahmed Z, Sarwar A, Jamil A, Anwer F. The potential vaccine component for COVID-19: a comprehensive review of global vaccine development efforts. Cureus. 2020;12(6):e8871. doi: 10.7759/cureus.8871.
    1. Goldman-Israelow B. Coronavirus replication cycle (template). ; 2020 [cited 2020 11/01/2020]; Available from: .
    1. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.
    1. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi: 10.1016/s0140-6736(20)30211-7.
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.
    1. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916–923. doi: 10.14309/ajg.0000000000000664.
    1. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115(5):766–773. doi: 10.14309/ajg.0000000000000620.
    1. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med. 2020;382:1370–1371. doi: 10.1056/NEJMc2003717.
    1. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663–1665. doi: 10.1056/NEJMc2005073.
    1. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706–711. doi: 10.1007/s11427-020-1661-4.
    1. Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China. J Infect Dis. 2020;221(11):1770–1774. doi: 10.1093/infdis/jiaa119.
    1. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveil. 2020;25:2000180. doi: 10.2807/1560-7917.
    1. Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410–411. doi: 10.1016/s1473-3099(20)30114-6.
    1. Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI, Ishihara T, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020. 10.1056/NEJMc2013020.
    1. Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. J Med Virol. 2020. 10.1002/jmv.25990.
    1. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58. doi: 10.1038/nrd.2018.168.
    1. Bauchner H, Fontanarosa PB. Randomized clinical trials and COVID-19: managing expectations. JAMA. 2020;323(22):2262–2263. doi: 10.1001/jama.2020.8115.
    1. Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. Current perspective of antiviral strategies against COVID-19. ACS Infect Dis. 2020;6:1624–1634. doi: 10.1021/acsinfecdis.0c00236.
    1. Malik S, Gupta A, Zhong X, Rasmussen TP, Manautou JE, Bahal R. Emerging therapeutic modalities against COVID-19. Pharmaceuticals (Basel) 2020;13(8):188. doi: 10.3390/ph13080188.
    1. COVID-19 Vaccine tracker. 2020 [cited 2020 08/08/2020]; Available from:.
    1. Kruse R. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 2; peer review: 2 approved] F1000Research. 2020;9:72. doi: 10.12688/f1000research.22211.2.
    1. Correia IR. Stability of IgG isotypes in serum. mAbs. 2010;2(3):221–232. doi: 10.4161/mabs.2.3.11788.
    1. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–963. doi: 10.1126/science.abc7520.
    1. Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–331. doi: 10.1021/acscentsci.0c00272.
    1. Chinese Clinical Trial Registry. A randomized controlled trial for the efficacy and safety of baloxavir marboxil, favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy. 2020. . Accessed 11/23/2020.
    1. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med 2020. 10.1056/NEJMoa2007764.
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047.
    1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.
    1. Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020;56:106114. doi: 10.1016/j.ijantimicag.2020.106114.
    1. Vankadari N. Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020;56(2):105998. doi: 10.1016/j.ijantimicag.2020.105998.
    1. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385. doi: 10.1038/nature17180.
    1. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653. doi: 10.1126/scitranslmed.aal3653.
    1. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2):e00221–e00218. doi: 10.1128/mBio.00221-18.
    1. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672–683. doi: 10.1021/acscentsci.0c00489.
    1. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327–2336. doi: 10.1056/NEJMoa2007016.
    1. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048–1057. doi: 10.1001/jama.2020.16349.
    1. FDA approves first treatment for COVID-19. Food and Drug Administration (FDA); 2020 [updated October 22, 2020; cited 2020 11/01/2020]; Available from:.
    1. Huang L, Zhang L, Liu Y, Luo R, Zeng L, Telegina I, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2017;2017:CD011489. doi: 10.1002/14651858.CD011489.pub2.
    1. Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The antiviral drug arbidol inhibits Zika virus. Sci Rep. 2018;8(1):8989. doi: 10.1038/s41598-018-27224-4.
    1. Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, et al. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol. 2019;93:e02185–e02118. doi: 10.1128/JVI.
    1. Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206–214. doi: 10.1073/pnas.1617020114.
    1. Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug Arbidol. PLoS One. 2011;6(1):e15874. doi: 10.1371/journal.pone.0015874.
    1. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV) Biosci Trends. 2020;14(1):69–71. doi: 10.5582/bst.2020.01020.
    1. Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379–381. doi: 10.1038/d41587-020-00003-1.
    1. Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917–921. doi: 10.1016/j.cmi.2020.04.026.
    1. Chen J, Lin S, Niu C, Xiao Q. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med. 2020:1–9. 10.1080/17476348.2020.1822741.
    1. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512. doi: 10.1016/j.pharmthera.2020.107512.
    1. Venkataraman S, Prasad B, Selvarajan R. RNA dependent RNA polymerases: insights from structure, function and evolution. Viruses. 2018;10(2):76. doi: 10.3390/v10020076.
    1. Shu B, Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016;113(28):E4005–E4014. doi: 10.1073/pnas.1602591113.
    1. Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79–81. doi: 10.1017/dmp.2014.151.
    1. Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38(8):653–671. doi: 10.1007/s40261-018-0656-y.
    1. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938.
    1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi: 10.1038/s41422-020-0282-0.
    1. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.
    1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discov Ther. 2020;14(1):58–60. doi: 10.5582/ddt.2020.01012.
    1. Zhu RF, Gao YL, Robert SH, Gao JP, Yang SG, Zhu CT. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19) J Transl Med. 2020;18(1):274. doi: 10.1186/s12967-020-02442-5.
    1. Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, et al. A Review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci. 2020;21(7):2657. doi: 10.3390/ijms21072657.
    1. Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–4779. doi: 10.1074/jbc.AC120.013056.
    1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi: 10.1016/s0140-6736(20)31022-9.
    1. NIH Clinical Trials. A trial of remdesivir in adults with mild and moderate COVID-19. . 2020.
    1. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363–382. doi: 10.1016/j.tips.2020.03.006.
    1. NIH Clinical Trials. A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia. . 2020.
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787–1799. doi: 10.1056/NEJMoa2001282.
    1. NIH Clinical Trials. Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure. . 2020.
    1. US Food & Drug Administration. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquin. 2020. . Accessed 06/15/2020.
    1. Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med. 2020;8(1):e17.
    1. Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents. 2020;56(3):106101. doi: 10.1016/j.ijantimicag.2020.106101.
    1. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. doi: 10.1016/j.medmal.2020.03.006.
    1. ter Meulen J, Bakker ABH, van den Brink EN, Weverling GJ, Martina BEE, Haagmans BL, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004;363(9427):2139–2141. doi: 10.1016/s0140-6736(04)16506-9.
    1. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10(8):871–875. doi: 10.1038/nm1080.
    1. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237. doi: 10.1371/journal.pmed.0030237.
    1. Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382–385. doi: 10.1080/22221751.2020.1729069.
    1. Puoci F. "Monoclonal-type" plastic antibodies for COVID-19 treatment: what is the idea? J Funct Biomater. 2020;11(2):43. doi: 10.3390/jfb11020043.
    1. Graham BS. Advances in antiviral vaccine development. Immunol Rev. 2013;255(1):230–242. doi: 10.1111/imr.12098.
    1. Afrough B, Dowall S, Hewson R. Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol. 2019;196(2):157–166. doi: 10.1111/cei.13295.
    1. Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187–1188. doi: 10.1126/science.abc4262.
    1. Fidel PL Jr, Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020;11(3):e00907–20. 10.1128/mBio.00907-20.
    1. Madan M, Pahuja S, Mohan A, Pandey RM, Madan K, Hadda V, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health. 2020;185:91–92. doi: 10.1016/j.puhe.2020.05.042.
    1. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. Engl J Med. 2020;383:1920–1931. 10.1056/NEJMoa2022483.
    1. Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601–2614. doi: 10.1038/s41467-020-16505-0.
    1. Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y, Liu R, Fu L, Zhang J, Guo Q, Wang C, Yang Y, Fang T, Lv P, Wang J, Xu J, Li J, Yu C, Hou L, Bu Z, Chen W. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 2020;11(1):4081–4088. doi: 10.1038/s41467-020-17972-1.
    1. Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with/without matrix-M adjuvan. NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: .
    1. A study to assess safety, tolerability, and immunogenicity of V591 (COVID-19 vaccine) in healthy participants (V591–001). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: .
    1. Clinical trial to evaluate the safety and immunogenicitiy of the COVID-19 Vaccine (COVID-19-101). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: .
    1. Ankcorn M, Gallacher J, Ijaz S, Taha Y, Harvala H, Maclennan S, et al. Convalescent plasma therapy for persistent hepatitis E virus infection. J Hepatol. 2019;71:434–438. doi: 10.1016/j.jhep.2019.04.008.
    1. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008;62(3):437–441. doi: 10.1093/jac/dkn243.
    1. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33–42. doi: 10.1056/NEJMoa1511812.
    1. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450–1451. doi: 10.1056/NEJMc070359.
    1. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46. doi: 10.1007/s10096-004-1271-9.
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490–9496. doi: 10.1073/pnas.2004168117.
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589. doi: 10.1001/jama.2020.4783.
    1. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561–1562. doi: 10.1001/jama.2020.4940.
    1. FDA. Recommendations for investigational COVID-19 convalescent plasma. . 2020.
    1. Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides tocilizumab? SGP130Fc. Cytokine: X. 2020;2:100029. doi: 10.1016/j.cytox.2020.100029.
    1. Buonaguro FM, Puzanov I, Ascierto PA. Anti-IL6R role in treatment of COVID-19-related ARDS. J Transl Med. 2020;18(1):165. doi: 10.1186/s12967-020-02333-9.
    1. Caocci G, La Nasa G. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Ann Hematol. 2020;99(7):1675–1676. doi: 10.1007/s00277-020-04067-6.
    1. Cascella M, Mauro I, De Blasio E, Crispo A, Del Gaudio A, Bimonte S, et al. Rapid and impressive response to a combined treatment with single-dose tocilizumab and NIV in a patient with COVID-19 pneumonia/ARDS. Medicina. 2020;56(8):377. doi: 10.3390/medicina56080377.
    1. Altschuler EL, Kast RE. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS) Med Hypotheses. 2020;141:109774. doi: 10.1016/j.mehy.2020.109774.
    1. Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res. 2015;38(9):1686–1701. doi: 10.1007/s12272-015-0640-5.
    1. Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin Transl Med. 2018;7(1):3. doi: 10.1186/s40169-017-0181-2.
    1. te Velthuis AJ. Common and unique features of viral RNA-dependent polymerases. Cell Mol Life Sci. 2014;71(22):4403–4420. doi: 10.1007/s00018-014-1695-z.
    1. Zhang WF, Stephen P, Theriault JF, Wang R, Lin SX. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J Phys Chem Lett. 2020;11(11):4430–4435. doi: 10.1021/acs.jpclett.0c00571.
    1. Qamar MTU, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313–319. doi: 10.1016/j.jpha.2020.03.009.
    1. Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60(6):3277–3286. doi: 10.1021/acs.jcim.0c00179.
    1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367:1444–1448. doi: 10.1126/science.abb2762.
    1. Whisenant J, Burgess K. Blocking coronavirus 19 infection via the SARS-CoV-2 spike protein: initial steps. ACS Med Chem Lett. 2020;11(6):1076–1078. doi: 10.1021/acsmedchemlett.0c00233.
    1. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi: 10.1038/s41586-020-2180-5.
    1. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894–904. doi: 10.1016/j.cell.2020.03.045.
    1. Zhang G, Pomplun S, Loftis AR, Tan X, Loas A, Pentelute BL. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD. bioRxiv. 2020. 10.1101/2020.03.19.999318.
    1. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039–2046. doi: 10.1056/NEJMoa012354.
    1. Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1–F19. doi: 10.1097/QAD.0b013e3282f4243b.
    1. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222. doi: 10.1038/s41467-019-13940-6.
    1. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256. doi: 10.1136/thorax.2003.012658.
    1. Lin S, Shen R, He J, Li X, Guo X. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases. bioRxiv. 2020. 10.1101/2020.01.31.929695
    1. Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnol. 2011;9:55. doi: 10.1186/1477-3155-9-55.
    1. Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527–2537. doi: 10.1002/ijc.22709.
    1. Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release. 2013;172(3):1020–1034. doi: 10.1016/j.jconrel.2013.10.012.
    1. Majumder J, Taratula O, Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev. 2019;144:57–77. doi: 10.1016/j.addr.2019.07.010.
    1. Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20(8):14051–14081. doi: 10.3390/molecules200814051.
    1. Cojocaru FD, Botezat D, Gardikiotis I, Uritu CM, Dodi G, Trandafir L, et al. Nanomaterials designed for antiviral drug delivery transport across biological barriers. Pharmaceutics. 2020;12(2):171–205. doi: 10.3390/pharmaceutics12020171.
    1. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–3174. doi: 10.1016/j.vaccine.2014.04.016.
    1. Huang X, Li M, Xu Y, Zhang J, Meng X, An X, et al. Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus. ACS Appl Mater Interfaces. 2019;11(22):19799–19807. doi: 10.1021/acsami.9b04240.
    1. Li Y, Lu J, Han Y, Fan X, Ding S-W. RNA interference functions as an antiviral immunity mechanism in mammals. Science. 2013;342(6155):231–234. doi: 10.1126/science.1241911.
    1. Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222–244. doi: 10.1016/j.jconrel.2020.07.011.
    1. Garbuzenko OB, Kuzmov A, Taratula O, Pine SR, Minko T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 2019;9(26):8362–8376. doi: 10.7150/thno.39816.
    1. Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500–518. doi: 10.1016/j.jconrel.2015.07.024.
    1. Savla R, Minko T. Nanotechnology approaches for inhalation treatment of fibrosis. J Drug Target. 2013;21(10):914–925. doi: 10.3109/1061186X.2013.829078.
    1. Minko T, Stefanov A, Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J Appl Physiol. 2002;93(4):1550–1560. doi: 10.1152/japplphysiol.00007.2002.
    1. Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm. 2013;84(2):335–344. doi: 10.1016/j.ejpb.2012.11.023.
    1. Garbuzenko OB, Ivanova V, Kholodovych V, Reimer DC, Reuhl KR, Yurkow E, et al. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s) Nanomedicine. 2017;13(6):1983–1992. doi: 10.1016/j.nano.2017.04.005.
    1. Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release. 2019;296:225–231. doi: 10.1016/j.jconrel.2019.01.025.
    1. El Kantar S, Nehmeh B, Saad P, Mitri G, Estephan C, Mroueh M, et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today. 2020. 10.1016/j.drudis.2020.08.002.
    1. Chandna P, Saad M, Wang Y, Ber E, Khandare J, Vetcher AA, et al. Targeted proapoptotic anticancer drug delivery system. Mol Pharm. 2007;4(5):668–678. doi: 10.1021/mp070053o.
    1. Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19(10):900–914. doi: 10.3109/1061186X.2011.622404.
    1. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107(23):10737–10742. doi: 10.1073/pnas.1004604107.
    1. Kim H. Outbreak of novel coronavirus (COVID-19): what is the role of radiologists? Eur Radiol. 2020;30(6):3266–3267. doi: 10.1007/s00330-020-06748-2.
    1. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843–1844. doi: 10.1001/jama.2020.3786.
    1. Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020;6(5):591–605. doi: 10.1021/acscentsci.0c00501.
    1. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589–594. doi: 10.1002/jmv.25725.
    1. Team C-I Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861–868. doi: 10.1038/s41591-020-0877-5.
    1. (FDA), Food and Drug Administration. Accelerated emergency use authorization (EUA) summary SARS-CoV-2 assay. Rutgers Clinical Genomics Laboratory. Nationwide Children’s Hospital; 2020. .
    1. Bhattarai KR, Kim HR, Chae HJ. Compliance with saliva collection protocol in healthy volunteers: strategies for managing risk and errors. Int J Med Sci. 2018;15(8):823–831. doi: 10.7150/ijms.25146.
    1. VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619–626. doi: 10.2144/000112776.
    1. Park GS, Ku K, Baek SH, Kim SJ, Kim SI, Kim BT, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) J Mol Diagn. 2020;22(6):729–735. doi: 10.1016/j.jmoldx.2020.03.006.
    1. Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(4):5135–5142. doi: 10.1021/acsnano.0c02823.
    1. Wang J, Cai K, Zhang R, He X, Shen X, Liu J, et al. Novel one-step single-tube nested quantitative real-time PCR assay for highly sensitive detection of SARS-CoV-2. Anal Chem. 2020;13:9399–9404. doi: 10.1021/acs.analchem.0c01884.
    1. Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, Andreoni M, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Dis. 2020;6:38. doi: 10.1038/s41420-020-0275-2.
    1. Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5(47):eabc6347. doi: 10.1126/sciimmunol.abc6347.
    1. Li JX. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. FDA, U.S. Food and Drug Administration. 2020. .
    1. Pan D, Pramanik M, Senpan A, Allen JS, Zhang H, Wickline SA, et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J. 2011;25(3):875–882. doi: 10.1096/fj.10-171728.
    1. Fraire JC, Perez LA, Coronado EA. Rational design of plasmonic nanostructures for biomolecular detection: interplay between theory and experiments. ACS Nano. 2012;6:3441–3452. doi: 10.1021/nn300474p.
    1. Zeng J, Zhang Y, Zeng T, Aleisa R, Qiu Z, Chen Y, Huang J, Wang D, Yan Z, Yin Y. Anisotropic plasmonic nanostructures for colorimetric sensing. Nano Today. 2020;32:100855. doi: 10.1016/j.nantod.2020.100855.
    1. Huang C, Wen T, Shi F-J, Zeng X-Y, Jiao Y-J. Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay. ACS Omega. 2020;5(21):12550–12556. doi: 10.1021/acsomega.0c01554.
    1. Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14:7617–7627. doi: 10.1021/acsnano.0c03822.
    1. Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek M, et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR. Nat Commun. 2020;11(1):4812. doi: 10.1038/s41467-020-18611-5.
    1. Lu R, Wu X, Wan Z, Li Y, Zuo L, Qin J, et al. Development of a novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Virol Sin. 2020;35(3):344–347. doi: 10.1007/s12250-020-00218-1.
    1. Hou T, Zeng W, Yang M, Chen W, Ren L, Ai J, et al. Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19. PLoS Pathog. 2020;16(8):e1008705. doi: 10.1371/journal.ppat.1008705.
    1. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol. 2020;9(5):e01136. doi: 10.1002/cti2.1136.
    1. Cozzi D, Albanesi M, Cavigli E, Moroni C, Bindi A, Luvarà S, et al. Chest X-ray in new coronavirus disease 2019 (COVID-19) infection: findings and correlation with clinical outcome. La Radiol Med. 2020;125(8):730–737. doi: 10.1007/s11547-020-01232-9.
    1. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87–93. doi: 10.2214/AJR.20.23034.
    1. Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am J Roentgenol. 2020;214(6):1280–1286. doi: 10.2214/AJR.20.22954.
    1. Buda N, Segura-Grau E, Cylwik J, Wełnicki M. Lung ultrasound in the diagnosis of COVID-19 infection - a case series and review of the literature. Adv Med Sci. 2020;65(2):378–385. doi: 10.1016/j.advms.2020.06.005.
    1. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32–E40. doi: 10.1148/radiol.2020200642.
    1. Fu F, Lou J, Xi D, Bai Y, Ma G, Zhao B, et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur Radiol 2020;30(10):5489–98. 10.1007/s00330-020-06920-8.
    1. Lee EYP, Ng M-Y, Khong P-L. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis. 2020;20(4):384–385. doi: 10.1016/s1473-3099(20)30134-1.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/s0140-6736(20)30183-5.
    1. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19) Radiology. 2020;295(3):715–721. doi: 10.1148/radiol.2020200370.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj